Evidence map›Paper›PMID 40705210›Full record

ArticleNeurochemical research2025

Avocado Oil Prevents Neurological and Behavioral Alterations in a Quinolinic Acid-Induced Model of Huntington's Disease.

Edith González-Guevara, Pablo Eliasib Martínez-Gopar, Alicia Sánchez-Mendoza, Quetzalli Denisse Angeles-López, Diego López-Orozco, Luis Tristán-López, Mohammed El-Hafidi, Mitzi Daniela Becerril-Cavazos, Claudia Peña-Segura, Carlos Alfredo Silva-Islas and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Neurochemical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Edith González-GuevaraLaboratorio de Neurofarmacología Molecular y Nanotecnología, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Avenida Insurgentes Sur No. 3877, Colonia La Fama. Alcaldía Tlalpan, Mexico City, CP 14269, Mexico.
Pablo Eliasib Martínez-GoparLaboratorio de Neurofarmacología Molecular y Nanotecnología, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Avenida Insurgentes Sur No. 3877, Colonia La Fama. Alcaldía Tlalpan, Mexico City, CP 14269, Mexico.
Alicia Sánchez-MendozaDepartamento de Farmacología, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico.
Quetzalli Denisse Angeles-LópezLaboratorio de Neurofarmacología Molecular y Nanotecnología, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Avenida Insurgentes Sur No. 3877, Colonia La Fama. Alcaldía Tlalpan, Mexico City, CP 14269, Mexico.
Diego López-OrozcoLaboratorio de Neurofarmacología Molecular y Nanotecnología, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Avenida Insurgentes Sur No. 3877, Colonia La Fama. Alcaldía Tlalpan, Mexico City, CP 14269, Mexico.
Luis Tristán-LópezLaboratorio de Neuroquímica, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Mexico City, Mexico.
Mohammed El-HafidiDepartamento de Biomedicina Cardiovascular, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico.
Mitzi Daniela Becerril-CavazosLaboratorio de Neurofarmacología Molecular y Nanotecnología, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Avenida Insurgentes Sur No. 3877, Colonia La Fama. Alcaldía Tlalpan, Mexico City, CP 14269, Mexico.
Claudia Peña-SeguraUnidad Académica de Bioterio, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, Mexico City, Mexico.
Carlos Alfredo Silva-IslasLaboratorio de Patología Vascular Cerebral, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Mexico City, Mexico.
Francisca Pérez-SeverianoLaboratorio de Neurofarmacología Molecular y Nanotecnología, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Avenida Insurgentes Sur No. 3877, Colonia La Fama. Alcaldía Tlalpan, Mexico City, CP 14269, Mexico. fperez@innn.edu.mx.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Avocado oil is a nutraceutical that offers multiple health benefits due to its rich composition of fatty acids. Avocado’s antioxidant molecules can protect from neuronal damage, potentially preventing or slowing down the onset of neurodegenerative diseases. Within the search for therapeutic targets in neurodegenerative conditions, we focused on testing the neuroprotective effect of the components contained in avocado oil in a Huntington’s disease (HD) model. Quinolinic acid (QA) is a potent striatal excitotoxin that leads to axon-sparing neurodegeneration and induces N-methyl-D-aspartate receptor-mediated cytotoxicity and neuroinflammation. The QA-lesioned rat striatum shares similarities with the neostriatum observed in individuals with HD. This work aimed to study the neuroprotective effects of an avocado oil-supplemented diet on the QA model by measuring neurological and oxidative damage. For this purpose, Wistar rats were fed with an avocado oil-supplemented diet for 20 days. First, evaluated blood biochemical parameters (glucose, cholesterol, and triglycerides) in the blood and testing liver function by the determination of hepatic enzymes levels in plasma and verifying that the avocado oil-supplemented diet did not affect either. Additionally, a second set of rats were fed with an avocado oil-supplemented diet and then lesioned with QA. Our results show that avocado oil supplementation reduces oxidative damage, prevents neurological damage by reducing the ipsilateral turns by maintaining the levels of striatal GABA content, and reduces striatal neurodegeneration assessed by Fluoro-Jade® B. These results suggest that an avocado oil-supplemented diet has a potential role in reducing the negative effects observed in the HD model of the QA intrastriatal administration.

Indexed as

Huntington DiseaseNeuroprotective AgentsPerseaPlant OilsQuinolinic AcidAnimalsDisease Models, AnimalMaleOxidative StressRatsRats, WistarNeuroprotective AgentsPlant OilsQuinolinic AcidAvocado oilHuntington diseaseNutraceuticalsOxidative damageQuinolinic acid

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.